Reading thru both analyst reports, what struck me is that Morgans do not touch on the likelihood or otherwise of the trial being successful. Indeed, all they really said was "We have set the price target at the same level. The risk to the target is a negative clinical trial read-out. FTT is recommended only for investors with a higher risk profile." In the Lodge Bros's report in contrast, they dwell significantly on this risk. Which investors, might I ask , were better informed after reading these reports?
- Forums
- ASX - By Stock
- DLM
- Ann: CEO presentation to Broker Meets Biotech - Perth
Ann: CEO presentation to Broker Meets Biotech - Perth, page-61
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLM (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DLM (ASX) Chart |
Day chart unavailable